Details.
Provides assistance for Combivir, Cabenuva, Dovato, Epivir, Epzicom, Juluca, Lexiva, Prezcobix, Retrovir, Rukobia, Selzentry, Tivicay, Tivicay PD, Triumeq, Triumeq PD, Trizivir, Viracept, and Ziagen. Financial eligibility is 500% FPL. Some products stopped accepting new applications in July 2022 or are scheduled for discontinuation.